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We compared outcomes for 2 retrospective cohorts of patients undergoing reduced-intensity conditioning
(RIC) therapy transplants using haploidentical related donors and post-transplant prophylaxis against graft-
versus-host disease (GVHD) with high-dose cyclophosphamide, tacrolimus, and mycophenolate. The ﬁrst
cohort of 13 was transplanted with bone marrow (BM) as the stem cell source, whereas the second cohort of
23 used peripheral blood stem cells (PBSCs) mobilized with granulocyte colony-stimulating factor. The BM
cohort received a single 60-mg/kg dose of cyclophosphamide on day þ3, whereas the PBSC cohort received
2 doses on days þ3 and þ4. Patients in the ﬁrst cohort were slightly older and had a higher proportion of
acute myeloid leukemia, but there were no differences in the distribution of Disease Risk Index scores
between the 2 groups. Patients in the PBSC group received double the number of CD34þ cells in the stem cell
graft. Times to neutrophil and platelet recovery were not different between the 2 groups. Three patients, all in
the PBSC group, failed to engraft but recovered with autologous hemopoiesis and survived. The 6-month
cumulative incidences of acute GVHD were 55.1% for BM and 48.5% for PBSCs (P ¼ .651), whereas
24-month cumulative rates for chronic GHVD were 28.6% for BM and 32.3% for PBSCs (P ¼ .685). Only 2
patients, both in the BM group, died of nonrelapse causes, both of second cancers. The 2-year cumulative
incidences of relapse were 43.9% for BM and 23.5% for PBSCs (P ¼ .286). Overall survival at 2 years was
signiﬁcantly better for PBSC patients (P ¼ .028), at 83.4% versus 52.7% for BM. Relapse-free and event-free
survival did not differ signiﬁcantly between BM and PBSC groups. In this retrospective analysis, we
conclude that the use of PBSCs for haploidentical RIC transplants is a feasible strategy, with equivalent rates of
acute and chronic GVHD and risk of relapse and low nonrelapse mortality compared with BM.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Allogeneic hemopoietic cell transplantation (alloHCT) is
widely used to treat a variety of serious hematological
malignancies, bone marrow (BM) failure syndromes, im-
mune deﬁciency states, and inherited disorders. The ideal
stem cell donor is a sibling fully matched for HLA coded by
the MHC located on chromosome 6. However, only around
30% of patients in need of an alloHCT have an HLA-matched
sibling. A matched volunteer unrelated donor is frequentlydgments on page 1644.
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ty for Blood and Marrow Transplantation.identiﬁed for patients lacking a matched relative, but the
likelihood of ﬁnding a suitable unrelated donor is highly
inﬂuenced by the ethnic background of the patient [1].
Alternative options for patients lacking HLA-matched related
or unrelated donors consist of unrelated umbilical cord blood
or relatives who share 1 HLA haplotype with the patient
(haploidentical relatives) [2,3].
Historically, the use of haploidentical donors was associ-
ated with high risks of graft rejection and graft-versus-host
disease (GVHD) [4]. However, the ﬁeld of haploidentical
alloHCT has been revolutionized in the last decade by the use
of high-dose cyclophosphamide soon after stem cell infusion
to delete alloreactive donor T lymphocytes infused with the
stem cell graft, resulting in relatively low rates of graft
rejection and GVHD [5,6]. Initially, BM harvested under
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the stem cell source [7-9]. However, more recently it has
been reported that hemopoietic cells mobilized into the
peripheral blood by administration of granulocyte colony-
stimulating factor (G-CSF) to donors could be used safely in
the context of haploidentical transplants [10,11].
We previously reported our experience of the use of
haploidentical BM transplants in a small cohort of patients
with hematological malignancies [9] and contributed to a
multicenter series of cases given G-CSFemobilized periph-
eral blood stem cells (PBSCs) from haploidentical relatives
[10]. However, the relative toxicity and efﬁcacy of the use
of these 2 sources of haploidentical stem cells remains un-
clear. In this study we compare outcomes of haploidentical
transplants using BM with an expanded cohort given
G-CSFemobilized PBSCs.METHODS
Patient demographic and disease details are summarized in Table 1. The
12 patients in the BM cohort were previously reported [9]. An additional
transplant was subsequently performed using BM, chosen instead of PBSCs
because the donor had splenomegaly due to b-thalassemia trait. In the PBSC
cohort, 10 patients were previously reported in a multicenter survey [10];
an additional 12 patients have subsequently been transplanted and are
included in this report. All patients lacked HLA-matched siblings, and
searches of international unrelated donor registries failed to identify a fully
matched donor or did not locate a donor who was able to undergo stem
cell collection within a clinically appropriate time frame. Searches of other
family members identiﬁed at least 1 haploidentical match. Patients
gave informed consent to undergo the procedure and for release of dei-
dentiﬁed data.
Details of transplant procedures were previously published [9,10]. In
brief, conditioning therapy consisted of the Baltimore nonmyeloablative
protocol, with cyclophosphamide 14.5 mg/kg daily i.v. on days 6 and 5,
ﬂudarabine 30 mg/m2 daily i.v. on days 6 to 2, and a single 2-Gy dose ofTable 1
Patient Demographic and Disease Details
BM
Group
(n ¼ 13)
PBSC
Group
(n ¼ 23)
Total
(N ¼ 36)
Median age, yr (range) 53
(27-63)
44
(23-69)
48
(23-69)
Sex, male/female 7/6 14/9 21/15
Diagnosis
AML 10 9 19
NHL 2 4 6
ALL 0 4 4
MDS 0 2 2
HL 0 1 1
SAA 0 2 2
CML 1 0 1
Other 0 1 1
DRI*
Low 3 1 4
Intermediate 6 15 21
High 4 4 8
Median CD34þ cells  106/kg
recipient body weight (range)
2.5
(1.3-4.8)
5.8
(2.0-10.0)
Median days to reach absolute
neutrophil count, .5  109/L
on 3 successive days (range)
15 (4-55) 16 (11-33)
Median days to reach sustained
platelet count of 20  109/L
on 3 successive days without
platelet transfusion
for 7 days (range)
18 (1-66)
(1 not
achieved)
24 (1-45)
NHL indicates non-Hodgkin lymphoma; MDS, myelodysplastic syndrome;
HL, Hodgkin lymphoma; SAA, severe aplastic anemia; CML, chronic myeloid
leukemia.
* Fisher’s exact test for comparison of distribution of DRI categories in BM
and PBSC groups, P ¼ .161.total body irradiation on day 17. In virtually all cases, conditioning therapy
and stem cell infusion were administered in the outpatient clinic. Hemo-
poietic cells, either harvested BM or PBSCs, were infused on day 0. All stem
cell grafts were unmanipulated, with no processing to remove T lympho-
cytes and no peritransplant in vivo administration of antieT cell antibodies.
Prophylaxis against GVHD consisted of cyclophosphamide 50 mg/kg i.v.
daily, given on dayþ3 in the case of BM grafts or as 2 daily doses on daysþ3
and þ4 in PBSC transplants, with an equivalent dose of mesna as urothelial
prophylaxis. In all cases, this was followed on day þ4 or þ5, respectively, by
oral tacrolimus, adjusted to produce a trough blood level of 5 to 15 ng/mL,
and in the absence of GVHD tapered between days 90 and 180, and myco-
phenolate mofetil 15 mg/kg 3 times daily orally until day 35 and then
weaned. Prophylaxis against infection consisted of ganciclovir 5 mg/kg i.v.
on days8 to1 for cytomegalovirus (CMV)-seropositive patients, acyclovir
800 mg twice daily for herpes simplexeseropositive patients, ﬂuconazole
400 mg daily as yeast prophylaxis, and penicillin and cotrimoxazole for
pneumococcal and Pneumocystis jiroveci prophylaxis, respectively. Trans-
fusions of RBC and platelet concentrates were given as clinically indicated.
G-CSF 5 mg/kg was given daily subcutaneously from day þ4 until neutrophil
recovery to .5109/L. Documentation of donor cell engraftment was carried
out by DNA chimerism analysis of ﬂow-sorted blood T lymphocytes and
granulocytes, according to previously published methods [9].
The closeout date for survival analyses was March 31, 2015. The main
outcome parameters examined were times to neutrophil and platelet count
recovery, graft rejection, incidence and severity of acute and chronic GVHD,
disease relapse, death without relapse, and overall, relapse-free, and event-
free survival. Acute and chronic GVHD were graded as previously published
[12,13]. Overall survival was calculated for all 36 patients. One patient in the
BM group with acute myeloid leukemia (AML), who had a myelodysplastic
relapse 49 months later, subsequently had a second haploidentical trans-
plant; he was censored from the survival analyses at the time of second
transplant. Three patients transplanted for nonmalignant conditions were
excluded from analysis of relapse and event-free survival. Relapse-free
survival was deﬁned as survival without relapse or death without relapse,
whereas event-free survival was deﬁned as survival without graft rejection,
relapse, or death without relapse. Competing factors for calculating cumu-
lative incidences of GVHD were relapse and death without relapse, whereas
for calculating cumulative incidence of relapse the competing factor was
death without relapse. Survival was calculated according to the method of
Kaplan and Meier [14].
RESULTS
Thirty-six consecutive reduced-intensity conditioning
(RIC) haploidentical transplants between April 2008 and
October 2014 are included in this report. Details are provided
in Table 1. Thirteen patients received BM grafts and 23
received PBSCs. Patients were aged between 23 and 69 years
(median, 48 years); PBSC patients were slightly younger
(median, 44 years; range, 23 to 69) than BM patients (me-
dian, 53 years; range, 27 to 63). Donors were siblings in 24
cases, sons in 6, daughters in 4, mothers in 2, and father in 1.
Nineteen patients had AML, 10 in the BM group and 9 in
PBSC (P ¼ .029). Six patients had non-Hodgkin lymphoma, 4
acute lymphoblastic leukemia (ALL) (3 were Philadelphia
chromosome positive), 2 myelodysplastic syndrome, 2 se-
vere aplastic anemia, and 1 each with Hodgkin lymphoma,
chronic myeloid leukemia, and metachromatic leukodystro-
phy. Three patients had the haploidentical transplant as a
rescue procedure after a failed ﬁrst transplant; 2 were
for graft rejection (rejection of a matched unrelated donor
graft for severe aplastic anemia and rejection of a mis-
matched unrelated cord blood graft for metachromatic leu-
kodystrophy), whereas one patient with Hodgkin lymphoma
relapsed after a matched unrelated donor transplant and
had a haploidentical transplant as salvage treatment. Of the
33 transplants for hematological malignancies, 4 were
classiﬁed as low risk, 21 as intermediate, and 8 as high by
the modiﬁed Disease Risk Index (DRI) criteria [15]. There
were no signiﬁcant differences in the distribution of DRI
categories between BM and PBSC groups (Table 1). Patients
receiving BM grafts were given a median CD34þ cell dose of
2.5  106/kg (range, 1.3 to 4.8), whereas those receiving
Figure 1. Overall survival of patients receiving haploidentical PBSC or BM
grafts: P ¼ .028.
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(range, 2.0 to 10.0) (P < .001).
Three patients, all receiving PBSCs, failed to engraft, but
survived; 2 of these had Philadelphia chromosomeepositive
ALL in ﬁrst remission, and both recovered with autologous
Philadelphia chromosomeenegative hemopoiesis. The third
patient had AML in second remission and because of morbid
obesity was unable to receive total body irradiation; he
recovered with autologous hemopoiesis. None had signiﬁ-
cant titers of antidonor HLA antibodies in their serum, and
there is therefore no obvious explanation for this happening
in the 2 ALL patients, both of whom had received signiﬁcant
prior chemotherapy. The remaining 33 patients engrafted,
with complete donor chimerism documented on DNA testing
of blood T cells and granulocytes. The time to neutrophil and
platelet recovery was not different between the BM and PBSC
groups (Table 1).
No serious episodes of opportunistic infection occurred in
either cohort. Of 25 patients,10 in the BM group and 15 in the
PBSC group, at high risk of CMV reactivation (seropositive
recipient, with seropositive or seronegative donor), 40%
experienced CMV reactivation (4 BM, 6 PBSC), but no cases of
CMV disease occurred. Therewere no cases of invasive fungal
infection, and no episodes of post-transplant lymphoproli-
ferative disease. Acute GVHD grades I to III was documented
in 18 patients, 7 in the BM group and 11 in the PBSC group.
Sixteen cases were overall grades I or II. Only 2 cases, both in
the PBSC group, had stage III disease, 1 with stage III skin and
stage II liver involvement and 1 with stage II skin and stage
I gastrointestinal disease. Both cases were corticosteroid
responsive. The distributions of cumulative incidence of
acute GVHD did not differ signiﬁcantly between BM and
PBSC groups (P¼ .651) and at 6 months were 55.1% (standard
error [SE], 14.1%) and 48.5% (SE, 10.5%), respectively. Four
patients in the BM group and 5 in the PBSC group developed
chronic GVHD, all limited stage; all 4 BM patients are now off
immunosuppressive therapy, whereas all 5 PBSC patients
remain on treatment. The cumulative incidence distributions
of chronic GHVD did not differ signiﬁcantly between BM and
PBSC groups (P ¼ .685), at 2 years 28.6% (SE, 14.4%) in the BM
group and 32.3% (SE, 13.3%) in the PBSC group.
Therewere nodeaths due to nonrelapse-related transplant
complications within the ﬁrst 6 months post-transplant. Two
BM patients died of secondary cancers 8 and 9 months post-
transplant, 1 from melanoma and 1 from lung cancer. One
patient died of acute GVHD after a second transplant (using
unrelated cord blood) following early post-haploidentical
transplant relapse of AML. With a median follow-up of 57
months in the BM group and 20months in the PBSC group,10
disease relapses occurred in the 33 patients with hematolog-
ical malignancies, 6 in the BM group (all AML) and 4 in the
PBSC group (2 myelodysplastic syndrome, 2 non-Hodgkin
lymphoma). The cumulative incidence distributions of
relapse did not differ signiﬁcantly between BM and PBSC
groups (P ¼ .286), at 2 years, 43.9% (SE, 15.3%) and 23.5% (SE,
10.3%), respectively. There were 5 progression-free survivors
in theBMgroup and21 in thePBSC group, including the3who
had graft rejection (2 remain on tyrosine kinase inhibitor
therapy for Philadelphia chromosomeepositive ALL). Three
patients transplantedwithPBSCs fornonmalignantconditions
remain alive and free of the underlying conditions, including
thepatientwithmetachromatic leukodystrophywhonowhas
normal aryl sulfatase levels in peripheral blood leucocytes.
Overall survival for all 36 patients differed signiﬁcantly
between the BM and PBSC groups (log rank test P ¼ .028;hazard ratio, 4.1; 95% conﬁdence interval, 1 to 16.0) and at
2 years post-transplant was 52.7% (SE, 14.1%) and 83.4% (SE,
8.9%), respectively (Figure 1). For the 33 patients with
hematological malignancies, the distribution of relapse-free
survival did not differ signiﬁcantly between BM and PBSC
groups (log rank test P ¼ .152) and at 2 years was 44.9% (SE,
14.1%) and 72.7% (SE, 10.5%), respectively. The distribution of
event-free survival also did not differ signiﬁcantly between
BM and PBSC groups (log rank test P ¼ .400) and at 2 years
was 44.9% (SE, 14.1%) and 63.6% (SE, 11.1%), respectively
(Figures 2 and 3).DISCUSSION
We report a retrospective series of consecutive hap-
loidentical transplants performed for serious blood diseases
using a uniform RIC protocol and post-transplant cyclo-
phosphamide as GVHD prophylaxis. Patients were trans-
planted in 2 cohorts, the ﬁrst using BM as the stem cell
source and the second with G-CSFemobilized PBSCs. The
major ﬁnding of this report is the relative safety of the
procedure, using either stem cell source. The only nonrelapse
deaths were 2 patients who developed secondary malig-
nancies within the ﬁrst year after transplant. No deaths
occurred because of opportunistic infections, which has been
reported to be a signiﬁcant problem in the setting of T
celledepleted haploidentical related PBSCs [3]. Similarly, no
deaths were attributable to acute GVHD. Although the
6-month cumulative incidence of acute GVHD was around
50%, most cases were grades I or II andmostly localized to the
skin, as reported by others [7,8,10]. The 24-month cumulative
incidence of chronic GVHD was also low, about 30%. These
data indicate the efﬁcacy of post-transplant cyclophospha-
mide in preventing GVHD, despite the major HLA mismatch
present in these patients. Equally, the risk of rejection was
low, with only 3 cases observed, 1 probably attributable to
attenuation of the conditioning regimen due to morbid
obesity.
One recent report compared outcomes between BM and
PBSC haploidentical transplants using the same reduced-
intensity protocol, with post-transplant cyclophosphamide
[11]. Castagna et al. reported a retrospective 2-center expe-
rience using the 2 stem cell sources, with 46 receiving BM
and 23 PBSCs. The major difference between their study and
Figure 2. Relapse-free survival for patients with hematological malignancies
receiving PBSC or BM grafts: P ¼ .152.
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most BM transplants, rather than tacrolimus. Similar to our
experience, there were no differences in neutrophil and
platelet recovery between the 2 groups, despite a higher
CD34 cell dose given to the PBSC patients. Nonrelapse
mortality was similar in both groups, 22% in BM and 12% in
PBSC, and predominantly due to infection. The incidence of
acute and chronic GVHD was also similar between BM and
PBSC groups (25% versus 33% for acute and 13% versus 13%
for chronic, respectively). It should be noted that patients in
the BM cohort received a single 60-mg/kg dose of cyclo-
phosphamide on day þ3, as previously reported, and not the
regimen used by others where 2 doses were given on
days þ3 and þ4 [7-9]. Although the use of a single cyclo-
phosphamide dose in the study by Luznik et al. [7] was
associated with an apparent increase in chronic GVHD
compared with 2 doses, we did not observe a signiﬁcant
difference between our 2 cohorts, perhaps because of the use
of PBSCs in the second cohort rather than BM. Overall
survival did not differ between the 2 groups.
The main problem encountered in our experience was
relapse of the underlying hematological malignancy. To aFigure 3. Event-free survival for patients with hematological malignancies
receiving PBSC or BM grafts: P ¼ .4.certain extent this was anticipated, because of the substan-
tial risk predicted by the DRI scores and the low intensity of
the conditioning therapy. No signiﬁcant difference were
found in DRI scores between the 2 cohorts in our study, and
with the relatively small numbers of patients in each cohort,
we could not detect a difference in relapse rate between the
2 cohorts. Castagna et al. [11] reported a higher cumulative
risk of relapse (33%) for patients transplanted while not in
remission compared with 14% for those in complete remis-
sion but also did not show a difference between BM and PBSC
patients. Potential strategies to overcome the risk of relapse
include donor lymphocyte infusion, which has been shown
to be feasible in this setting, or increasing the intensity of the
conditioning therapy [16,17].
This study has limitations, in particular the retrospective
collection of data and the differences in the duration of
follow-up for survivors in the 2 cohorts. The latter, and the
relatively small numbers and heterogeneous composition of
the 2 cohorts, limits the generalizability of interpretation of
our ﬁndings. We also cannot exclude possible biases
resulting from alterations in patient selection during the
study, due to experience gained using this protocol,
although we did not note any differences in the DRI scores
between the groups. Nevertheless, the encouraging overall
survival experienced in the PBSC cohort provides a rationale
for further exploring this strategy in future prospective
clinical trials.
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